US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Abstract The global atopic dermatitis drugs market was estimated at 4.1 (USD Billion) in 2019 and is projected to hit the revenue of 5.09 (USD Billion) by 2025 at a CAGR of around 4.34% over the period from 2019 to 2025. The report offers valuation and analysis of the atopic dermatitis drugs market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on value (USD Billion). Introduction Atopic dermatitis is common, serious, and inflammatory skin disorders that largely affect the child population. The inflammatory skin conditions include psoriasis, tinea, erythroderma, and dermatitis. According to NCBI, atopic dermatitis affects nearly twenty percent of children and ten percent of adults in developed nations. For the record, atopic dermatitis affects nearly 13% of children and 10% of adults in the U.S. Furthermore, the patients and their families have felt a large impact on the quality of life as a well fiscal burden. The clinical characteristics of atopic dermatitis include excoriations, crusting, erythema, oozing, lichenification, and edema. Additionally, pruritus is the major property of atopic dermatitis and produces comorbidities like mental distress and sleep loss, thereby creating a huge affliction to parents as well as patients. Reportedly, genetic aspects and ecological factors strongly impact atopic dermatitis. Additionally, there is a large occurrence of the disorder in emerging nations. The disease exemplifies massive heterogeneity in the medical severity, disease phenotype, persistence, response to the treatment, and persistence. The key goals of treating the disease through drugs are to reduce inflammation of the skin as well as pruritus and flare prevention. Market Growth Dynamics New concepts in disease pathogenesis have prompted research & development activities for creating novel medicines to treat disease. Additionally, a large spectrum of medicines is utilized for treating skin disease and they include steroids, moisturizing creams, and calcineurin inhibitors. All these beneficial aspects are anticipated to drive the growth of the atopic dermatitis drugs market over the forecast timeline. Apart from this, the introduction of biologic medicines has helped treat atopic dermatitis. Additionally, new biologic drugs including dupilumab and crisaborole are also used for treating atopic dermatitis. Reportedly, the former drug was first approved for treating atopic dermatitis in adults across the regions such as Japan, North America, and Europe. For the record, dupilumab is the only biologic medicine approved by the European Medicines Agency and the U.S. Food and Drug Administration for treating adult subjects. Moreover, biologic medicines can treat adult patients as these drugs provide convenient dose schedules and assist in effective lab monitoring as compared to other forms of systemic treatments along with reduced side effects. All these factors are anticipated to bring a paradigm shift in the atopic dermatitis drugs industry over the forthcoming years. North American Market To Acquire Numero Uno Position By 2025 The growth of the regional market over the forecast period is subject to surge in the incidences of atopic dermatitis in children along with rising in the frequency of skin allergies in adult population in the countries like the U.S. Apparently, launching of new drugs in the foreseeable future will further enlarge the business scope over the ensuing years. Key players included in the atopic dermatitis drugs market are: Meda Pharmaceuticals Bayer AG Encore Dermatology Leo Pharma Valent Pharmaceutical Inc. The global atopic dermatitis drugs market is segmented as follows: By Therapy Photo Therapy Directed Therapy By Route of Administration Injectable Clinics Research Labs By End User Injectable Clinics Research Labs Key Industry Development In Aug 2020, LEO Pharma A/S announced the sale of a portfolio of four non-core products to Cheplapharm for EUR 300 million. The agreement represents a milestone in the roll-out of LEO Pharma’s 2030 strategy which increases the company’s focus on new innovative solutions for medical dermatology. The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©(Alfacalcidol), Locoid©(Cortisol), Pimafucin©(Natamycin), and Zineryt©(Erythromycin 40 mg and Zinc Acetate dihydrate). The annual turnover of the portfolio in 2019 amounted to approximately EUR 110 million. The transaction is expected to close by December 2020, subject to satisfaction of customary closing conditions, including receipt of regulatory approvals. Following the closing, LEO Pharma and Cheplapharm will work closely together to ensure a smooth and effective transition of the products and business. By Region North America The U.S. Canada Europe France The UK Spain Germany Italy Rest of Europe Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC South Africa Rest of Middle East & Africa
Table of Contents Request Table Of Content Click To Request Sample Chapter 1. Preface 1.1. Report Description and Scope 1.2. Research Scope 1.3. Research Methodulogy 1.3.1. Market Research Process 1.3.2. Market Research Methodulogy Chapter 2. Executive Summary 2.1. Atopic Dermatitis Drugs Market, 2016–2025 (USD Billion) 2.2. Atopic Dermatitis Drugs Market: Snapshot Chapter 3. Global Atopic Der | read more...